Key Points
In this article, Dr. Liu argues that:
- Separating nicotine from combustion is essential. The pharmacology of nicotine differs fundamentally from the toxicology of tobacco smoke, and regulatory debates must reflect that distinction.
- Animal models remain critical for causal clarity. Because human data is often confounded by prior smoking history, controlled experimental models are necessary to isolate respiratory and cardiovascular risks.
- Developmental and cross-generational effects require urgent study. Long-term cohort research is needed to assess how electronic nicotine delivery may affect brain development and metabolic health.
- Advanced modeling tools should complement traditional toxicology. Integrating computational methods and machine learning can help regulators assess the wide variability of products and formulations.
- Science must lead policy. Standardized research methods and greater international data-sharing are essential to ensure that harm reduction debates remain evidence-driven.
Disclaimer: The views expressed in this article are solely those of the author and do not necessarily reflect those of 2Firsts.
Xin-an Liu, Ph.D.
Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences
Founding Member, Nicotine Science Exchange（NSE）
February 24, 2026
The recent risk assessment report by the French Agency for Food, Environmental and Occupational Health & Safety (ANSES) provides a balanced evaluation of electronic cigarettes. The report concludes that e-cigarettes are likely less harmful than combustible tobacco, yet significant scientific uncertainties remain. Among the most important challenges are the lack of long-term data, extreme product heterogeneity, and confounding effects from prior smoking history.
From a neuroscientist’s perspective, these uncertainties are not reasons for inaction. Instead, they define a research agenda. As electronic nicotine delivery systems become widely used across populations, science must advance at the same pace.
Nicotine Is Not Combustible Tobacco
A central scientific issue is the need to distinguish nicotine itself from the toxic mixture produced by tobacco combustion. In our recent study (Jia et al., Advanced Science, July 2025), we found that chronic oral nicotine exposure in aged mice reprogrammed aging-related metabolic pathways and was accompanied by improved motor performance. These findings do not suggest that nicotine is harmless. Rather, they emphasize that the long-term biological effects of nicotine alone are not equivalent to those of cigarette smoke, which contains thousands of combustion-derived toxicants.
Nicotine is a neuromodulator acting primarily through nicotinic acetylcholine receptors. It influences dopamine signaling, mitochondrial metabolism, inflammation, and synaptic plasticity. Tobacco smoke, by contrast, introduces carcinogens, oxidants, and particulates that drive cancer, chronic lung disease, and vascular injury. If harm-reduction science is to be rigorous, it must carefully separate nicotine pharmacology from combustion toxicology.
Biological Complexity: Dose, Route, and Developmental Stage
Nicotine is biologically complex. Its effects depend on dose, duration, delivery route, and developmental context.
At the Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, our laboratory utilizes well-established animal models to investigate the systemic and neural effects of nicotine. Our data suggest that:
- Low versus high doses can produce distinct physiological outcomes;
- Inhaled (aerosolized) nicotine differs substantially from oral or injectable delivery;
- Adolescents, adults, and aged individuals may respond differently.
Electronic cigarettes add another layer of complexity: devices vary in heating temperature, aerosol chemistry, and nicotine concentration. Human epidemiological studies often cannot precisely control for these variables. Therefore, well-designed animal models remain essential. Under controlled conditions, they allow us to dissect causal mechanisms safely before translation to human studies.
Neurodevelopment and Transgenerational Questions
One of the most urgent knowledge gaps concerns developmental exposure.
Nicotinic receptors play key roles in brain development, influencing neuronal migration, synaptic refinement, and circuit formation. Exposure during pregnancy or adolescence may alter executive function, reward processing, or addiction vulnerability. Yet long-term developmental data specific to electronic nicotine delivery remain limited. Our ongoing research, together with evidence from other laboratories' published studies, explores the cross-generational neuro-metabolic effects of nicotine exposure. Early findings suggest that nicotine may induce persistent metabolic changes. Whether such effects translate to humans requires careful longitudinal study. If electronic cigarettes are widely used among reproductive-age populations, long-term birth cohort studies should be initiated without delay.
Cardiovascular and Systems-Level Effects
The ANSES report notes short-term cardiovascular responses associated with nicotine, such as increased heart rate and blood pressure. However, definitive long-term outcomes remain uncertain.
Nicotine influences sympathetic activity, vascular tone, and mitochondrial energetics. Chronic adaptation may differ from acute responses, particularly under low-dose, intermittent inhalation patterns typical of e-cigarette use.
Addressing these questions requires:
- Rigorous long-term cardiovascular studies in validated animal models;
- Comprehensive multi-omics profiling of metabolic and inflammatory mechanisms;
- Well-designed clinical investigations of nicotine pharmacokinetics and systemic physiological effects.
Only integrated systems-level research can clarify whether nicotine-containing e-cigarettes pose sustained cardiovascular risks.
The Role of AI and International Collaboration
Electronic cigarettes present a unique scientific challenge: extreme product heterogeneity. Thousands of flavors and device configurations create enormous variability in exposure. Traditional toxicology alone cannot efficiently evaluate this landscape.
Our team is integrating machine learning approaches to model chemical formation in aerosols, predict receptor interactions, and analyze addiction-related neural responses. The long-term goal is to build structured databases linking chemical composition, toxicology, neurobehavioral outcomes, and population-level data. Such efforts require international collaboration. Regulatory agencies including the U.S. Food and Drug Administration, public health institutions, and research laboratories should work collaboratively to share data and harmonize research methodologies. Cross-population studies are particularly important, as genetic and environmental backgrounds may influence nicotine’s biological effects. Nicotine harm reduction is a global issue. The science supporting it must also be global.
Moving Forward: A Clear Research Path
Compared to combustible tobacco—studied for more than a century—electronic cigarettes are relatively new. Yet their adoption has been rapid and widespread.
From a scientific standpoint, several priorities are clear:
- Distinguish nicotine’s pharmacological effects from combustion-related toxicity.
- Standardize dose- and route-specific preclinical models.
- Launch long-term developmental and transgenerational studies.
- Integrate AI-based predictive toxicology.
- Strengthen international cooperation and shared databases.
Harm reduction must be guided by evidence rather than ideology. Electronic cigarettes may represent a reduced-risk alternative for adult smokers, but reduced risk does not mean zero risk. At the same time, uncertainty should motivate research—not polarization.
As scientists, our responsibility is to investigate carefully, communicate transparently, and collaborate globally. Only through rigorous and forward-looking research can nicotine harm reduction policy rest on solid scientific foundations.
2Firsts welcomes submissions from scientists, researchers, and subject-matter experts.For inquiries or submissions, please contact: alan@2firsts.com
(Cover Photo: Dr. Xin-an Liu speaks at the 2Firsts 2025 Next-Generation Tobacco Seminar. Source: 2Firsts.)
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
